Clinical Research

Effects of Ayurvedic treatment on 100 patients of chronic renal failure (other than diabetic nephropathy)

Manish V. Patel¹, S. N. Gupta², Nimesh G. Patel³

¹Lecturer, ²Professor and Head, Department of Kayachikitsa, JS Ayurved College, PD Patel Ayurved Hospital, Nadiad, ³Resident Medical Officer, PD Patel Ayurved Hospital, Nadiad, Gujarat, India

Abstract

Chronic renal failure (CRF) refers to an irreversible deterioration in renal function, which develops over a period of years. This initially manifests only as a biochemical abnormality. CRF is considered when glomerular filtration rate (GFR) falls below 30 ml/min. The conventional approach of management includes dialysis and renal transplantation, which are not affordable by Indian population mainly due to economic reasons. Therefore, exploration of a safe and alternative therapy is needed, which proves to be helpful in reducing the requirement of dialysis and in postponing the renal transplantation. A clinical study of 100 patients of CRF was conducted at OPD and IPD of PD Patel Ayurved Hospital, Nadiad. They were given Niruha basti of Punarnavadi kvatha daily with oral medicaments including Goksuradi guggulu, Rasayana churna, and Varunadi kvatha for 1 month period. The patients of CRF, having diabetic nephropathy as a cause, were excluded since a separate study for diabetic nephropathy is being conducted. Results were analyzed statistically using the “t” test. The symptoms and signs, serum creatinine, blood urea, urine albumin level were reduced, which were found to be statistically highly significant on “t” test.

Key words: Ayurveda, chronic renal failure, Niruha basti

Introduction

Chronic renal failure (CRF) is a global threat to health in general and for developing countries in particular because therapy is expensive and lifelong. In India, 90% patients cannot afford the cost. CRF refers to an irreversible deterioration in renal function which classically develops over a period of years. Initially, it is manifested only as a biochemical abnormality. Eventually, loss of the excretory, metabolic and endocrine functions of the kidney leads to the development of the clinical symptoms and signs of renal failure, which are referred to as uraemia. When death is likely without renal replacement therapy (RRT), it is called end-stage renal failure (ESRF).[1] It would be interesting to know that the incidence of chronic kidney disease in India, which is a densely populated country with low income, different food, cultural traditions and lifestyle habits, is 7.85 million CRF patients of its 1 billion population and the prevalence rate is 0.78%.[2]

Over 1 million people worldwide are alive on dialysis or with a functioning graft.[3] It is estimated that by 2010, 6 million people worldwide would need RRT costing US $28 billion.[4] As per the December 2007 index declared by Rajya Sabha, the per capita income in India is ₹ 20,734 per annum. The total population is 113 crore of which 26% live below the poverty line (BPL) where the daily earning is ₹ 10 only.[5] The monthly cost of hemodialysis (HD) in most private hospitals averages ₹ 12,000 and the yearly cost of dialysis is ₹ 140,000. The average cost of kidney transplant varies from ₹ 50,000 in a government set-up to ₹ 300,000 in an average private hospital. Also, the yearly maintenance cost post transplant for the drugs amounts to ₹ 120,000 per year or ₹ 10,000 per month. So, the social and economic consequences of CRF are considerable and the conventional approach of management includes dialysis and renal transplantation which is not affordable and acceptable by Indian population. Therefore, exploration of a safe and alternative therapy is highly needed, which proves to be helpful in reducing the requirement of dialysis and in postponing the renal transplantation. Several institutes and scholars are making possible attempts in this direction.

Prashanth et al. studied the role of Punarnavadi compound in the management of CRF in 2008–2009 and found it effective and safe.[6]

We obtained some encouraging results during the management of the patients of CRF with certain Ayurvedic treatments.
These significantly correct uremia, which is the cardinal feature of CRF, and improve the renal function which is evident by reduction in serum creatinine and blood urea. In addition, the treatments also improve the general condition of the patient.

**Aims and objectives**
1. To prove the efficacy of the Ayurvedic preparations in management of CRF.
2. To give the scientific establishment to the observations which show that certain Ayurvedic treatments significantly correct albuminuria and serum creatinine value, which are the cardinal features of CRF, and improve the renal function which is evident by reduction in serum creatinine and blood urea levels.
3. To provide a large human population suffering from CRF, a future possibility of a treatment which can be helpful in reducing the need of HD and to avoid or to delay renal transplantation.

**Materials and Methods**

All the patients were selected from the OPD and IPD of the PD Patel Ayurved Hospital, Nadiad.

**Criteria for inclusion**

Patients with clinically positive history of CRF, having the clinical features of CRF like albuminuria, raised serum creatinine and blood urea, were included.

**Criteria for exclusion**

1. The patients having diabetic nephropathy were excluded from this study.
2. Patients who were on dialysis therapy.
3. Patients with other added complications.

**Plan of study and management**

1. The patients were treated in OPD as well as in IPD.
2. A total of 100 patients with CRF were registered for the study [Table 1].
3. The patients were treated with the following:
   - **Gokshuradi guggulu** (compound Ayurvedic preparation: Gokshura + Guggulu + Triphala + Trikatu + Musta) 1 g three times a day.
   - **Rasayan churna** (Gokshura + Amalaki + Guduchi in equal quantities) 3 g two times a day.
   - **Varunadi kvath** (ingredients: Varuna tvak + Bilva moola + Aparamarga + Chitrak moola + Arani + Shigru + Bruhati + Kirattikta + Karanja + Shatavari) 10 g two times/day.
   - **Niruha basti** of Punarnavadi kvatha\(^7\) daily.
4. The patients were kept on normal healthy diet.
5. The doses of the continuous antihypertensive drugs of the patients were not interfered with.

**Preparation of medicines**

Medicines were prepared under expert supervision and purchased from Sunder Ayurveda pharmacy, Nadiad.

**Duration of the treatment**

The duration of the treatment was 1 month.

**Assessment of the results**

1. All the patients were clinically assessed before and after treatment.
2. Changes in symptoms, albuminuria, serum creatinine, blood urea and hemoglobin were observed.
3. Observations were evaluated statistically.

**Results and Observations**

The main causative factor for CRF in this study was hypertension; 96% patients were found in this group. 7% patients were having chronic nephritis and 5% were having polycystic kidney disease. Only 2% of the patients were found with obstructive nephropathy [Table 1]. Serum creatinine reduced by 20.71% and it was statistically highly significant. Blood urea reduced by 32.15% and it was also statistically highly significant. Albuminuria reduced by 36.70% and this was statistically highly significant. Hemoglobin increased by 4.65% and this was statistically highly significant [Table 2]. None of the patients had shown any new and unusual feature. Urine output increased by 56.4% and it was statistically highly significant. Out of 100 patients, edema was reported by 58 patients and it reduced by 71.36%. Nausea was reported in 46 patients and it was relieved by 68.75%. The 24 patients were found to have vomiting and it was relieved by 82.35%. Weakness was found in 85 patients and it reduced by 55.61%. The 53 patients were having loss of appetite, and appetite increased by 59.29%. Leg cramps were found in 17 patients and it reduced by 72%. Breathlessness was found in 27 patients and it was relieved by 64.29%. Hiccup was found in only one patient and was totally relieved. The 19 patients reported pruritus and it reduced by 66.66% [Table 3]. Reductions in all these symptoms were statistically highly significant.

**Discussion and Interpretation**

As mentioned earlier, CRF is specific form of renal disease. According to Ayurveda, CRF is a disease of Mutravaha Srotas. Though all the three Doshas as well as all the Dushyas are involved in the disease, Kapha is responsible in blocking microvessels and developing microangiopathy. Vata is responsible for degeneration of the structure of the kidney. According to Ayurvedic principles of management of the disease, tissue damage can be prevented and repaired by Rasayana drugs because they have the capability to improve qualities of tissues and hence increase resistance of the tissues. On the other hand, blockage can be removed by Lekhana drugs having scraping effect on blocked channels.

Gokshuradi guggulu\(^9\) (combined Ayurvedic preparation) is Rasayana for Mutravaha Srotas and it has also Lekhana (scraping) effect because of Guggulu\(^9\) (Commiphora mukul). Varunadi kvath\(^10\) is also helpful to relieve the Kapha and Vata doshas. Rasayan churna has Rasayan properties.\(^11\) Niruha basti is a minor alternative of dialysis. A total of 100 patients

| Table 1: Basic underlying cause of chronic renal failure |
|-------------------------------------------------------|
| Basic cause                                           | No. of patients | Percentage |
| Hypertension                                         | 86              | 86         |
| Chronic nephritis                                    | 07              | 07         |
| Polycystic kidney disease                            | 05              | 05         |
| Obstructive nephropathy                              | 02              | 02         |
of CRF were taken for the research study. In this study, it was found that serum creatinine reduced by 20.71% with treatment. This beneficial effect was statistically highly significant which is encouraging and shows improvement in kidney functions. Blood urea reduced by 36.15% with treatment and it was also statistically highly significant. Treatment resulted in reduction in albuminuria by 36.70% and increase in hemoglobin by 4.65%, which were statistically highly significant. Reduction in edema, weakness, leg cramps, increase in appetite, and relief from nausea, breathlessness and pruritus were statistically highly significant.

**Conclusion**

With the help of clinical observations and the discussion made, it may be concluded that 86% patients of CRF have hypertension as a basic underlying cause. The result obtained may be attributed to the disease modifying effect of trial therapy by means of its *Rasayana* and anti Vata–Kapha properties.

The trial therapy is an ideal drug as a safe and effective alternative in case of CRF.

Serum creatinine, blood urea and albuminuria reduced 20.71%, 32.15% and 36.70%, respectively. Hemoglobin level and urine output increased by 4.38% and 56.54%, respectively. They were statistically highly significant. All the patients have shown more than 50% relief in all the signs and symptoms. In a difficult condition where conventional treatments are beyond the financial capacities of a common man of the country, this therapy can be hopeful and promising.

---

### References

1. Davidson S. Davidson’s Principles and Practice of Medicine. 20th ed. Philadelphia: Churchill Livingstone Elsevier publication; 2006. p. 485.
2. Dash SC, Agarwal SK. All India institute of medical sciences, Nephrology, New Delhi, India. “Incidence of Chronic kidney disease in India” - Letter in Oxford Journal. Oxford: Oxford University; 2009. p. 21.
3. Lysaght MJ. Maintenance dialysis population dynamics: Current trends and long-term implications. Published by J Am Soc Nephrol 2002;13:S37-40.
4. Khanna U. The Economics of Dialysis in India. Indian J Nephrol 2009;19:1-4. (This sentence given as a reference of Bethesda, MD, Atlas of End Stage Renal disease in the United States, US Renal data system. USRDS 2000 Annual Data Report: 2000).
5. Modi GK, Jha V. The incidence of end stage renal disease in India, a population based study. Kidney Int 2006;70:21-31.
6. Prashanth GS, Baghel MS, Gupta SN, Ravishankar. “A clinical study on the management of C.R.F with Punarnavadi Compound” – Ph.D. Thesis. India: G.A.U; 2009.
7. Govinddas Sen, Bhashyajya Ratnavali, Udara rogadhikar, Adhyaya 40-44 edited by Brahma shankara Mishra. 11th ed. Varanasi: Chaukhambha Sanskrit Sansthan; 1993.
8. Sarangdhara Samhita, Madhyamakhanda, Adhyaya 7/85-88, edited by harishankara bhatta. 2nd ed. Mumbai: Pandit Narayan Mulaji Sanskrit pustakalaya; 1928.
9. Bhavagruhacarya, Bhavangraha Samhita(gujarati bhasantara sahita), Madhyamakhanda, Adhyaya 7/85-88, edited by harishankara bhatta. 2nd ed. Mumbai: Pandit Narayan Mulaji Sanskrit pustakalaya; 1928.
10. Govinddas Sen, Bhavagruhacarya, Karpuradi Varga, 38 – 40, edited by Vishvanath Divedi. 9th ed. Varanasi: Motilal Banarasidas Prakashan; 1998. p. 107. Pandit Narahari, Raj Nighantu, Candonodi Varga, 105. 1st ed. Varanasi: Krishnadas Acaderny; 1982.
11. Shastri Shankar Daji Pade, Aryabhishak, Purvvardh – Vanashadhadi Gunadarshi/41, 22nd ed. Ahmedabad: Sastushiya Mudranalay Trust; 2004. p. 102.
Announcement

Android App

A free application to browse and search the journal’s content is now available for Android based mobiles and devices. The application provides “Table of Contents” of the latest issues, which are stored on the device for future offline browsing. Internet connection is required to access the back issues and search facility. The application is compatible with all the versions of Android. The application can be downloaded from https://market.android.com/details?id=comm.app.medknow. For suggestions and comments do write back to us.